Open AccessAnthrax lethal factor represses glucocorticoid and progesterone receptor activity
Author(s) -
Jeanette I. Webster,
Leonardo H. Tonelli,
Mahtab Moayeri,
S. Stoney Simons,
Stephen H. Leppla,
Esther M. Sternberg
Publication year - 2003
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.1036973100
Subject(s) - transactivation , glucocorticoid receptor , progesterone receptor , biology , psychological repression , nuclear receptor , receptor , mineralocorticoid receptor , anthrax toxin , kinase , transcription factor , estrogen receptor , microbiology and biotechnology , biochemistry , gene expression , gene , genetics , recombinant dna , cancer , breast cancer , fusion protein
We report here that a bacterial toxin, anthrax lethal toxin (LeTx), at very low concentrations represses glucocorticoid receptor (GR) transactivation in a transient transfection system and the activity of an endogenous GR-regulated gene in both a cellular system and an animal model. This repression is noncompetitive and does not affect ligand binding or DNA binding, suggesting that anthrax lethal toxin (LeTx) probably exerts its effects through a cofactor(s) involved in the interaction between GR and the basal transcription machinery. LeTx-nuclear receptor repression is selective, repressing GR, progesterone receptor B (PR-B), and estrogen receptor alpha (ERalpha), but not the mineralocorticoid receptor (MR) or ERbeta. GR repression was also caused by selected p38 mitogen-activated protein (MAP) kinase inhibitors, suggesting that the LeTx action may result in part from its known inactivation of MAP kinases. Simultaneous loss of GR and other nuclear receptor activities could render an animal more susceptible to lethal or toxic effects of anthrax infection by removing the normally protective antiinflammatory effects of these hormones, similar to the increased mortality seen in animals exposed to both GR antagonists and infectious agents or bacterial products. These finding have implications for development of new treatments and prevention of the toxic effects of anthrax.